CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma
|
|
- Damon Stevenson
- 5 years ago
- Views:
Transcription
1 AJCP /CASE REPORT CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma Yuan Miao, MD, 1,2 Pei Lin, MD, 1 Wei Wang, MD, 1 L. Jeffrey Medeiros, MD, 1 and Xinyan Lu, MD 1 From the 1 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston; and 2 Department of Pathology, The First Affiliated Hospital and the College of Basic Medical Science of China Medical University, Shenyang. Key Words: Mantle cell lymphoma (MCL); CCND1-IGH gene fusion-amplification; MYC copy number gain; CD5 negative; Pleomorphic variant Am J Clin Pathol December 2016;146: DOI: /AJCP/AQW194 ABSTRACT Objectives: Mantle cell lymphoma (MCL) may present de novo or undergo progression to a clinically aggressive variant, known as a blastoid or pleomorphic variant. We report an unusual case of classic MCL in a 78-year-old man with a typical immunophenotype, including CD5 positivity, who subsequently relapsed with CD5-negative pleomorphic variant MCL. Methods: Biopsy specimens were evaluated using Wright- Giemsa stained or H&E-stained sections, flow cytometry, immunohistochemistry, conventional cytogenetic, nextgeneration sequencing, and fluorescence in situ hybridization. Results: The patient continued to be refractory to intensive chemotherapy and radiation therapy. Initial conventional cytogenetic analysis showed a complex karyotype with amplification of the CCND1-IGH fusion gene on the der(14): 44, Y, t(x;2)(p22.3;q21), del(2)(p21), del(6)(p23), add(7)(p22), 9, del(9)(p22), add(11)(q13), 13, add(14)(p11.2), der(14)t(11;14)(q13;q32)hsr(14)(q32), add(18)(q23), add(21)(p11.1), 22,þmar[12]. A repeat biopsy revealed MCL, pleomorphic variant, with loss of CD5 expression and extra copies of the MYC. Mantle cell lymphoma (MCL) represents 3% to 10% of all cases of non-hodgkin lymphoma. Virtually all cases carry t(11;14)(q13;q32)/ccnd1-igh and overexpress cyclin D1. 1,2 Morphologically, the classic type is characterized by small cells with hyperchromatic nuclei. Blastoid and pleomorphic variants of MCL are aggressive variants and usually accompanied by complex genetic changes and sometimes an atypical immunophenotype. 3 The presence of MYC abnormalities, including MYC copy number gain and MYC rearrangement, have been correlated with these morphologic variants and predict poorer survival in patients with MCL. 4 The occurrence of an amplified CCND1-IGH fusion is very rare in lymphomas. This event has been described in one case of MCL and one case of plasma cell leukemia; both patients had an aggressive clinical course. 5,6 To our knowledge, there are no reports of patients with MCL who had CCND1-IGH fusion gene amplification associated with blastoid or pleomorphic variant MCL. In this study, we report a unique MCL case with an amplified CCND1-IGH fusion gene. At the time of relapse, the MCL had morphologic features of a pleomorphic variant, CD5 expression was lost, and MYC copy number gain was identified. Conclusions: CCND1-IGH fusion-amplification with MYC copy number gain is extremely rare and may play a role in disease progression in a subset of MCL cases. Case Report A 78-year-old man developed symptoms of increased fatigue, dyspnea, and drenching night sweats in September American Society for Clinical Pathology, All rights reserved. For permissions, please journals.permissions@oup.com 747 Am J Clin Pathol 2016;146: DOI: /ajcp/aqw194
2 Miao et al / CCND1-IGH FUSION-AMPLIFICATION AND MYC COPY NUMBER GAIN IN MCL Physical examination revealed a 4-cm left groin mass and a 5-cm upper right arm mass. Laboratory studies showed that the WBC count was /L (reference range, /L) with many lymphoma cells identified and a serum lactic dehydrogenase level of 1,100 IU/L (reference range, IU/L). Subsequent bone marrow aspiration and biopsy confirmed the diagnosis of MCL (classic, CD5þ). The patient underwent six cycles of bendamustine and rituximab and two cycles of rituximab and hyperfractionated cyclophosphamide but did not have any response. In July 2015, the patient was treated with three cycles of rituximab, gemcitabine, cisplatin, and dexamethasone but again failed to respond, and his disease continued to progress. In October 2015, after progression, a repeat biopsy sample taken from the lymph node of the left pelvis and a lateral retroperitoneal mass showed CD5- negative pleomorphic MCL. The patient received radiation therapy to the right upper arm, left groin, and left abdominal mass. However, a subsequent positron emission tomography scan displayed overall progression. The patient then received salvage chemotherapy with dexamethasone, rituximab, lenalidomide, and bortezomib. The chemotherapy was eventually discontinued due to development of severe and persistent neuropathy. The patient was discharged to an inpatient hospice in December Materials and Methods Morphology and Immunohistochemistry Wright-Giemsa stained bone marrow aspirate smears and H&E-stained histologic sections of bone marrow, left pelvic lymph node, and lateral retroperitoneal mass were reviewed. Immunohistochemical stains were performed using formalin-fixed, paraffin-embedded tissue sections. The antibodies used were specific for PAX5, CD5, CD10, CD79a, and Ki-67 (DAKO, Carpinteria, CA); SOX11 and c-myc (Ventana Medical Systems, Tucson, AZ); and cyclin D1 (NeoMarkers, Fremont, CA). Flow Cytometry Immunophenotypic Analysis The diagnostic bone marrow (BM), peripheral blood (PB), and lateral retroperitoneal biopsy specimens at relapse were assessed by flow cytometry immunophenotyping. The antibody panel included reagents specific for CD5, CD11c, CD19, CD20, CD22, CD23, CD25, CD30, CD38, CD43, CD44, CD79b, CD81, CD103, CD200, FMC-7, and surface immunoglobulin j and k light chains. All antibodies were obtained from Becton-Dickinson Biosciences (San Jose, CA). Conventional Cytogenetic and Fluorescence In Situ Hybridization Analyses Conventional cytogenetic analysis was performed at the time of the initial diagnosis, according to the standard laboratory procedures. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature Fluorescence in situ hybridization (FISH) analysis using a dual-color/dual-fusion probe set for CCND1-IGH rearrangements; a dual-color, break-apart rearrangement probe for BCL2 and MYC; and a panel of five locus-specific probes (ATM, TP53, D12Z3, D13S319, andlamp1 loci) for chronic lymphocytic leukemia (CLL) were performed on cultured initial diagnostic bone marrow cells. All probes were purchased from Abbott Molecular (Des Plaines, IL). Molecular Analysis Genomic DNA was extracted from the initial diagnostic bone marrow aspirate. A panel of 53 genes targeting TP53, ATM, KIT, NPM1, KRAS, NRAS, IDH1, APC, TET2, ASXL1, and other genes was assessed using a next-generation sequencing based assay as described previously. 8 Results Morphology The diagnostic bone marrow aspirate smears showed many monotonous small lymphoma cells, and the biopsy section showed complete replacement by lymphoma cells with mature chromatin and scant cytoplasm. After progression, left pelvic lymph node biopsy and lateral retroperitoneal mass biopsy specimens showed diffuse sheets of large lymphoid cells with irregular nuclear contours, occasionally prominent nucleoli, and moderate cytoplasm Image 1. Immunophenotypic Analysis Initially, flow cytometric immunophenotyping of the BM aspirate specimen showed that the lymphocytes were positive for CD5, CD19, CD20, CD22, FMC7, and immunoglobulin k light chain and were negative for CD11c, CD23, CD25, CD43, CD103, CD200, and immunoglobulin j light chain. Flow cytometric immunophenotyping in the PB showed 83% lymphoma cells positive for CD5, CD19, CD20, CD22, CD43 (dim), CD79b, CD81, and immunoglobulin k light chain and negative for CD3 and immunoglobulin j light chain. After progression, flow cytometric analysis of the lateral retroperitoneal biopsy specimen showed a population of aberrant B cells positive for CD11c (partial), CD19 (dim), CD20 (dim), CD22 (partial), CD Am J Clin Pathol 2016;146: American Society for Clinical Pathology 748 DOI: /ajcp/aqw194
3 AJCP / CASE REPORT B C D E F A Image 1 Morphology and immunocytochemistry. H&E staining in bone marrow: low-power (A) and high-power (B) H&E staining in a lateral retroperitoneal biopsy specimen (C) and immunohistochemical stains of cyclin D1 (D), MYC (E), and Ki-67 (F) in a lateral retroperitoneal biopsy specimen (A, 100; B-F, 400). American Society for Clinical Pathology 749 Am J Clin Pathol 2016;146: DOI: /ajcp/aqw194
4 Miao et al / CCND1-IGH FUSION-AMPLIFICATION AND MYC COPY NUMBER GAIN IN MCL A B C E D Image 2 Fluorescence in situ hybridization (FISH) and cytogenetic analysis. Conventional karyotype results (A). FISH with the CCND1-IGH dual-color, dual-fusion, locusspecific probes in the bone marrow aspirate showing the presence of the t(11;14)(q13;q32) and amplification of CCND1-IGH fusion gene (B). Chronic lymphocytic leukemia (CLL) panel FISH results showed a normal signal patterns for ATM (green) and TP53 (red; C). CLL panel showed a heterozygous D13S319 deletion (red) and no evidence of trisomy 12 (green) or deletion of the LAMP1 gene (aqua; D). MYC FISH using the dual-color break-apart probe showing four copies of the MYC gene (arrows) with no evidence of rearrangement (E). (1,000) 750 Am J Clin Pathol 2016;146: American Society for Clinical Pathology 750 DOI: /ajcp/aqw194
5 AJCP /CASE REPORT (partial), CD44, CD79b (dim), and monotypic immunoglobulin k light chain and negative for CD5, CD10, CD23, CD30, CD43, and CD200. Immunohistochemical analysis of the left pelvic lymph node biopsy sections showed the lymphoma cells were positive for CD79a and cyclin D1 and negative for CD5 and CD10. In the lateral retroperitoneal mass biopsy slides, the lymphoma cells were positive for PAX5, cyclin D1, and MYC and negative for SOX11. The proliferation (Ki-67) index was about 80% (Image 1). Conventional Cytogenetic, FISH, and Molecular Analyses Conventional cytogenetic analysis on the diagnostic BM aspirate specimen showed a complex karyotype containing t(11;14)(q13;q32) with a homogeneously staining region (HSR) involving an CCND1-IGH amplification: 44, Y, t(x;2)(p22.3;q21), del(2)(p21), del(6)(p23), add(7)(p22), 9, del(9)(p22), add(11)(q13), 13, add(14)(p11.2), der(14) t(11;14)(q13;q32)hsr(14)(q32), add(18)(q23), add(21) (p11.1), 22,þmar[12]. Amplified nuclear fusion signals were observed in 90% of the interphases Image 2A. FISH on the initial BM aspirate specimen confirmed the CCND1-IGH fusion-amplification tobeanhsronchromo- some 14q32 Image 2B. A CLL panel showed no evidence of TP53 or ATM deletions Image 2C but a heterozygous D13S319 deletion in 76% of cells, which was consistent with the monosomy 13 Image 2D. The results of other loci for the CLL FISH panel were all negative. The 53-gene mutation panel showed no evidence of any mutations for the genes targeted, including TP53 and ATM. After progression, additional FISH analysis on the lateral retroperitoneal biopsy specimen showed no evidence of MYC or BCL2 rearrangement but with extra copies of MYC (arrows; Image 2E ). No materials from the lymph node biopsy specimen were available for chromosome analysis or for other FISH and molecular testing. Discussion WereportauniquecaseofMCLwiththeamplificationof the CCND1-IGH fusion and MYC copy number gain. The patient had aggressive disease and a refractory clinical course. After treatment, the tumor lost CD5 expression and histologically progressed from classic MCL to a pleomorphic variant. Previous studies have shown that aggressive variants of MCL arise in a patient with a previously documented classic MCL. However, the immunophenotype of the transformed disease usually is similar to its predecessor. 9 Although CD5 expression of lymphoid cells is sometimes negative in aggressive variants, CD5 loss has not been associated specifically with a pleomorphic variant. 10 Our patient represents a rare event in MCL with CD5 expression converting from positive to negative during morphologic transformation. Pleomorphic and blastoid variants of MCL are nearly always accompanied by great genetic complexity. 3 MYC abnormalities, including MYC copy number gain and MYC rearrangement, have been associated with aggressive variants of MCL and likely contribute to its adverse clinical outcome. 4 Interestingly, in the present case, using conventional karyotyping and FISH, the amplified CCND1-IGH rearrangement formed an HSR at 14q32. Gene fusion-amplification in general is a very rare event in hematologic malignancies. To our knowledge, only two cases of CCND1-IGH fusionamplification have been reported, one in plasma cell leukemia and one in leukemic MCL. 5,6 Including our case, both CCND1-IGH fusion-amplification MCL cases showed additional complex chromosomal changes. However, the previously reported MCL case also had TP53 gene mutation and amplification of the ATM gene; the composite changes make it difficult to ascertain whether CCND1-IGH fusionamplification was the cause for the rapid clinical progression. 5 In our patient, although there were very complex chromosomal aberrations, the patient had no other mutations or amplifications except for extra MYC copies or heterozygous D13S319 deletion, and it is likely that the CCND1-IGH fusion-amplification along with a complex karyotype may lead to an aggressive clinical course. In summary, we present an unusual case of MCL associated with CCND1-IGH fusion-amplification, CD5 antigen loss, transformation to a pleomorphic variant, and MYC copy number gain. This patient had a very aggressive clinical course. To our knowledge, this is the first case of MCL associated with CCND1-IGH fusion-amplification that subsequently transformed to a pleomorphic variant. Although a single unusual case report cannot lead to a conclusion that CCND1-IGH gene fusion-amplification contributes to the histologic or immunophenotypic evolution in MCL, an integrated approach to MCL diagnosis, by incorporating clinical features, morphology, immunophenotype, and genetic/genomic findings, is needed to accurately diagnose and risk-stratify these unusual cases. Corresponding author: Xinyan Lu, MD, Dept of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; xlu4@mdanderson.org. References 1. Vose JM. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2015;90: American Society for Clinical Pathology Am J Clin Pathol 2016;146: DOI: /ajcp/aqw194
6 Miao et al / CCND1-IGH FUSION-AMPLIFICATION AND MYC COPY NUMBER GAIN IN MCL 2. Bertoni F, Zucca E, Cotter FE. Molecular basis of mantle cell lymphoma. Br J Haematol. 2004;124: Shrestha R, Bhatt VR, Guru Murthy GS, et al. Clinicopathologic features and management of blastoid variant of mantle cell lymphoma. Leuk Lymphoma. 2015;56: Yi S, Zou D, Li C, et al. High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival. Oncotarget. 2015;6: Gruszka-Westwood AM, Atkinson S, Summersgill BM, et al. Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion gene. Genes Chromosomes Cancer. 2002;33: Ishigaki T, Sasaki K, Watanabe K, et al. Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case. Cancer Genet Cytogenet. 2010;201: Simons A, Shaffer LG, Hastings RJ. Cytogenetic nomenclature: changes in the ISCN 2013 compared to the 2009 edition. Cytogenet Genome Res. 2013;141: Luthra R, Patel KP, Reddy NG, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014;99: Kasamon YL, Burns KH. Blastic transformation of mantle cell lymphoma. Blood. 2012;120: Morice WG, Hodnefield JM, Kurtin PJ, et al. An unusual case of leukemic mantle cell lymphoma with a blastoid component showing loss of CD5 and aberrant expression of CD10. Am J Clin Pathol. 2004;122: Am J Clin Pathol 2016;146: American Society for Clinical Pathology 752 DOI: /ajcp/aqw194
Case 3. Ann T. Moriarty,MD
Case 3 Ann T. Moriarty,MD Case 3 59 year old male with asymptomatic cervical lymphadenopathy. These images are from a fine needle biopsy of a left cervical lymph node. Image 1 Papanicolaou Stained smear,100x.
More informationDifferential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
More informationCase Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent
Int J Clin Exp Med 2014;7(1):307-311 www.ijcem.com /ISSN:1940-5901/IJCEM1311029 Case Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent Qilin Ao 2, Ying Wang 1, Sanpeng Xu 2,
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationInitial Diagnosis and Treatment 81 Male
Case SH2017-0359 Shiraz Fidai 1, Sandeep Gurbuxani 1, Girish Venkataraman 1, Gordana Raca 2, Madina Sukhanova 3, Michelle M Le Beau 3, Y. Lynn Wang 4, Mir Alikhan 4, Megan M.McNerney 4, Yuri Kobzev 4,
More informationThe patient had a mild splenomegaly but no obvious lymph node enlargement. The consensus phenotype obtained from part one of the exercise was:
Case History An 86 year old male was admitted to hospital with chest infection. Haematological examination subsequently revealed the following: Hb- 11.0 g/dl; WBC- 67.1 x 10^9/l; PLT- 99 x10^9/l; RBC-
More informationChronic Lymphocytic Leukemia FISH Panel. Impact on Diagnosis
Hematopathology / CLL, FISH, AND 14Q32 TRANSLOCATIONS Chronic Lymphocytic Leukemia FISH Panel Impact on Diagnosis Beverly P. Nelson, MD, 1 Rohit Gupta, MD, 1 Gordon W. Dewald, PhD, 2 Sarah F. Paternoster,
More informationCost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic
Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship
More informationCLL Complete SM Report
Reported: 02/01/2012 Σ CGI ID No:5 Client:r Client Address: CLINICAL DATA: Lymphoma No CBC results provided. CLL Complete SM Report FINAL DIAGNOSIS: CD19+ B cell lymphoma, ZAP-70 + (44%), with borderline
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationImmunophenotypic Profile of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Hematopathology / IMMUNOPHENOTYPE OF LPL/WM Immunophenotypic Profile of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Sergej Konoplev, MD, PhD, L. Jeffrey Medeiros, MD, Carlos E. Bueso-Ramos,
More informationPathology of the indolent B-cell lymphomas Elias Campo
Pathology of the indolent B-cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas Antigen selection NAIVE -B LYMPHOCYTE MEMORY B-CELL MCL FL LPL MZL CLL Small cell
More informationLymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients
Hematopathology / LYMPHOMAS WITH IGM PARAPROTEIN Lymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients Pei Lin, MD, 1 Suyang Hao, MD, 1* Beverly C. Handy, MD, 2 Carlos E. Bueso-Ramos,
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationHIGH GRADE B-CELL LYMPHOMA DAVID NOLTE, MD (PGY-2) HUSSAM AL-KATEB, PHD, FACMG DEBORAH FUCHS, MD
HIGH GRADE B-CELL LYMPHOMA DAVID NOLTE, MD (PGY-2) HUSSAM AL-KATEB, PHD, FACMG DEBORAH FUCHS, MD OUTLINE High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements Patient presentation 2008/2016
More informationHematopathology Service Memorial Sloan Kettering Cancer Center, New York
SH2017-0334 t(14;18) Negative Follicular Lymphoma with 1p36 abnormality associated with In Situ Follicular Neoplasia with t(14;18) translocation Pallavi Khattar MD, Jennifer Maerki MD, Alexander Chan MD,
More informationThe Role of CD11c Expression in the Diagnosis of Mantle Cell Lymphoma
Hematopathology / CD11c Expression in Mantle Cell Lymphoma The Role of CD11c Expression in the Diagnosis of Mantle Cell Lymphoma Teresa S. Kraus, MD, * Christine N. Sillings, MD, * Debra F. Saxe, PhD,
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More information7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
More informationImmunopathology of Lymphoma
Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.
More informationBlastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and
More informationPhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA
PhenoPath Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA C urrent diagnosis of B cell non-hodgkin lymphoma (B-NHL) is based on the 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid
More informationHEMATOPATHOLOGY SUMMARY REPORT RL;MMR;
HEMATOPATHOLOGY SUMMARY REPORT RL;MMR; Page 1 of 1 05/15/20XX HP000000-20XX 05/21/20XX (212) 123-457 (51) 32-3455 (51) 123-457 Age: 78 DOB: 0/05/19XX SS#: 45-45-45 Clinical Information: 78 y/o female with
More informationABERRANT EXPRESSION OF CD19 AND CD43
ABERRANT EXPRESSION OF CD19 AND CD43 IN A PATIENT WITH THERAPY-RELATED ACUTE MYELOID LEUKEMIA AND A HISTORY OF MANTLE CELL LYMPHOMA Yen-Chuan Hsieh, 1 Chien-Liang Lin, 2 Chao-Jung Tsao, 2 Pin-Pen Hsieh,
More informationTest Utilization: Chronic Lymphocytic Leukemia
Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.
More informationB-lymphoblastic transformation of mantle cell lymphoma/leukemia with double hit changes
J Hematopathol (2015) 8:31 36 DOI 10.1007/s12308-014-0229-9 CASE REPORT B-lymphoblastic transformation of mantle cell lymphoma/leukemia with double hit changes Michael E. Kallen & Nagesh P. Rao & Sameer
More informationThe spectrum of flow cytometry of the bone marrow
The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests
More informationMantle Cell Lymphoma
HEMATOPATHOLOGY Original Article Mantle Cell Lymphoma Morphologic Findings in Bone Marrow Involvement JAY WASMAN, MD, 1 NANCY S. ROSENTHAL, MD,' AND DIANE C. FARHI, MD 2 Although mantle cell lymphoma (MCL),
More informationAggressive B-cell Lymphomas Updated WHO classification Elias Campo
Aggressive B-cell Lymphomas Updated WHO classification Elias Campo Hospital Clinic, University of Barcelona Diffuse Large B-cell Lymphoma A Heterogeneous Category Subtypes with differing: Histology and
More informationMethods used to diagnose lymphomas
Institut für Pathologie Institut für Pathologie Methods used to diagnose lymphomas Prof. Dr.Med. Leticia Quintanilla-Fend Molecular techniques NGS histology Cytology AS-PCR Sanger seq. MYC Immunohistochemistry
More informationLeukemic Phase of Mantle Cell Lymphoma, Blastoid Variant
Hematopathology / LEUKEMIC BLASTOID MANTLE CELL LYMPHOMA Leukemic Phase of Mantle Cell Lymphoma, Blastoid Variant Timothy P. Singleton, MD, Margaret M. Anderson, MD, Charles W. Ross, MD, and Bertram Schnitzer,
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version: CLLBiomarkers 1.0.0.2 Protocol Posting Date: June 2017
More informationGray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-NHLs Burkitt Lymphoma Burkitt-Like Lymphoma DLBCL Patrick Tres
Gray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-NHLs Burkitt Lymphoma Burkitt-Like Lymphoma DLBCL Patrick Treseler, MD, PhD University of California San Francisco
More informationClassification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
More informationCase Report Synchronous Pulmonary Squamous Cell Carcinoma and Mantle Cell Lymphoma of the Lymph Node
Case Reports in Genetics Volume 2011, Article ID 945181, 5 pages doi:10.1155/2011/945181 Case Report Synchronous Pulmonary Squamous Cell Carcinoma and Mantle Cell Lymphoma of the Lymph Node Yu Sun, 1 Yun-Fei
More informationSignificance of Chromosome Changes in Hematological Disorders and Solid Tumors
Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome 3.3 X 10 9 DNA basepairs Estimated genetic constitution 30,000
More informationSignificance of Chromosome Changes in Hematological Disorders and Solid Tumors
Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome! Estimated genetic constitution! Size of average chromosome
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationFollicular Lymphoma: the WHO
Follicular Lymphoma: the WHO and the WHERE? Yuri Fedoriw, MD Associate Professor of Pathology and Laboratory Medicine Director of Hematopathology University of North Carolina Chapel Hill, NC Disclosure
More informationClinicopathologic features of 112 cases with mantle cell lymphoma
Cancer Biol Med 2015;12:46-52. doi: 10.7497/j.issn.2095-3941.2015.0007 ORIGINAL ARTICLE Clinicopathologic features of 112 cases with mantle cell lymphoma Dong-Mei Zhou, Gang Chen, Xiong-Wei Zheng, Wei-Feng
More informationPatient Case Studies & Panel Discussion
Patient Case Studies & Panel Discussion Panelists: Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center; Ranjana H. Advani, MD, Stanford Cancer Institute; Andrew D. Zelenetz, MD, PhD, Memorial
More informationSuccessful flow cytometric immunophenotyping of body fluid specimens
Successful flow cytometric immunophenotyping of body fluid specimens Fiona E. Craig, MD Division of Hematopathology Mayo Clinic Arizona 2017 MFMER slide-1 Financial disclosure No conflicts 2017 MFMER slide-2
More informationPatterns of Lymphoid Neoplasia in Peripheral Blood. Leon F. Baltrucki, M.D. Leon F. Baltrucki, M.D. Disclosure
Patterns of Lymphoid Neoplasia in Peripheral Blood Leon F. Baltrucki, M.D. Leon F. Baltrucki, M.D. Disclosure Dr Baltrucki has received an honorarium for his participation as a faculty presenter in this
More informationAggressive B-cell Lymphomas
Neoplastic Hematopathology Update 2018 Aggressive B-cell Lymphomas Raju K. Pillai City of Hope National Medical Center I do not have any disclosures Disclosures Outline New entities and changes in WHO
More informationMast Cell Disease Case 054 Session 7
Mast Cell Disease Case 054 Session 7 Rodney R. Miles, M.D., Ph.D. Lauren B. Smith, M.D. Cem Akin, M.D. Diane Roulston,, Ph.D. Charles W. Ross, M.D. Departments of Pathology and Internal Medicine University
More informationIntegrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University
Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic
More informationThe development of clonality testing for lymphomas in the Bristol Genetics Laboratory. Dr Paula Waits Bristol Genetics Laboratory
The development of clonality testing for lymphomas in the Bristol Genetics Laboratory Dr Paula Waits Bristol Genetics Laboratory Introduction The majority of lymphoid malignancies belong to the B cell
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationHematopathology Case Study
www.medfusionservices.com Hematopathology Case Study CV3515-14 JUNE Clinical Presentation: Clinical Information: A 42 year old male with history of chronic myelogenous leukemia (CML) presents with an elevated
More informationCitation International Journal of Hematology, 2013, v. 98 n. 4, p The original publication is available at
Title Diagnostic challenges in a case of B cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma Author(s) So, JCC; Yung, KH; Chu, ML; Wan,
More informationB-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia. A Report of Four Cases
AJCP / Case Report B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia A Report of Four Cases Zaher Chakhachiro, MD, C. Cameron Yin, MD, PhD, Lynne V. Abruzzo, MD, PhD, Tariq N. Aladily,
More informationFrom Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport
From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology Songlin Zhang, MD, PhD LSUHSC-Shreveport I have no Conflict of Interest. FNA on Lymphoproliferative
More informationThe clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia
444 2016 USCAP, Inc All rights reserved 0893-3952/16 $32.00 The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia Yan Li, Shimin Hu, Sa A Wang, Shaoying Li, Yang O Huh, Zhenya
More informationDiagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation
Case Study Diagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation Ling Wang 1 and Xiangdong Xu 1,2,* 1 Department of Pathology, University of California, San Diego; 2
More informationFISH VALIDATION: HOW I DO IT!
FISH VALIDATION: HOW I DO IT! Theresa C. Brown, PhD, FACMG, CG(ASCP) CM Director, Cytogenetics laboratory Hayward Genetics Center Instructor Tulane University School of Medicine WHERE DO I GET THIS INFORMATION
More informationUse of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma
Use of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma Dr Anthony Bench Haematopathology and Oncology Diagnostic Service Cambrıdge Unıversıty Hospitals NHS Foundatıon Trust Cambridge
More informationChronic Lymphocytic Leukemia Mantle Cell Lymphoma Elias Campo
Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas NAIVE -B LYMPHOCYTE MEMORY CELL CLL MCL FL MZL Small cell size Low proliferation
More informationCanadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010
Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination May 4, 2010 Examination Length = 3 hours Total Marks = 100 (7 questions) Total Pages = 8 (including cover sheet and 2 pages of prints)
More informationHematopathology Case Study
Hematopathology Case Study AMP Outreach Course 2009 AMP Annual Meeting John Greg Howe Ph.D. Department of Laboratory Medicine Yale University School of Medicine November 19, 2009 HISTORY Case History An
More informationCase #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed
Case #1 65 yo man with no prior history presented with leukocytosis and circulating blasts: WBC 187.4K/uL ; Hgb 10.0gm/dL; Platelet 68K/uL Neutrophil % 25.0% Lymphocyte % 38.0% Monocyte % 12.0% Metamyelocyte
More informationADx Bone Marrow Report. Patient Information Referring Physician Specimen Information
ADx Bone Marrow Report Patient Information Referring Physician Specimen Information Patient Name: Specimen: Bone Marrow Site: Left iliac Physician: Accession #: ID#: Reported: 08/19/2014 - CHRONIC MYELOGENOUS
More informationParticipants Identification No. % Evaluation
BMD-02 Cell Identification Participants Identification No. % Evaluation Erythrocyte precursor, normal 228 95.8 Educational Erythrocyte, normal 7 3.0 Educational Erythrocyte precursor with megaloblastic
More informationTEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days
TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome
More informationPearls and pitfalls in interpretation of lymphoid lesions in needle biopsies
Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies Megan S. Lim MD PhD University of Pennsylvania October 8, 2018 Objectives To understand how the trend toward less invasive lymph
More informationMantle Cell Lymphoma Mainly Involving Thoracic Lesions: Two Case Reports
CASE REPORT Mantle Cell Lymphoma Mainly Involving Thoracic Lesions: Two Case Reports Makoto Kosaka 1, Tomonobu Koizumi 1, Toshirou Fukushima 1, Yousuke Wada 1, Toshihiko Agatsuma 1, Toshiki Yokoyama 1,
More informationComposite mantle cell and follicular lymphoma. A case report
Human Pathology (2009) 40, 259 263 www.elsevier.com/locate/humpath Case study Composite mantle cell and follicular lymphoma. A case report Raquel B. Ilgenfritz MD a,, Agnès Le Tourneau MD a, Michel Arborio
More informationNIH Public Access Author Manuscript Leuk Lymphoma. Author manuscript; available in PMC 2015 February 27.
NIH Public Access Author Manuscript Published in final edited form as: Leuk Lymphoma. 2013 January ; 54(1): 174 176. doi:10.3109/10428194.2012.691484. Transformed large B-cell lymphoma in rituximab-allergic
More informationMantle cell lymphoma with features of marginal-zone lymphoma
J Hematopathol (2011) 4:7 11 DOI 10.1007/s12308-011-0084-x ORIGINAL ARTICLE Mantle cell lymphoma with features of marginal-zone lymphoma Ulla Randen & Olav Erich Yri & Anne Tierens & Sverre Heim & Klaus
More informationGENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute
GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute B and T cell monoclonalities Rearrangement of immunoglobin and TCR genes may help
More informationHaematology Probes for Multiple Myeloma
Haematology Probes for Multiple Myeloma MULTIPLE MYELOMA Multiple myeloma (MM) is a plasma cell neoplasm, characterised by the accumulation of clonal plasma cells in the bone marrow and by very complex
More informationVolume 7, Issue 1 January 2012
The Hong Kong College of Pathologists, Incorporated in Hong Kong with Limited Liability Volume 7, Issue 1 January 2012 Editorial note: Chronic lymphocytic leukaemia (CLL) is the commonest chronic lymphoproliferative
More informationDefined lymphoma entities in the current WHO classification
Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationOutlines. Disclosures. Updates on B-cell Chronic Lymphoproliferative Disorders of the Blood and Bone Marrow
Updates on B-cell Chronic Lymphoproliferative Disorders of the Blood and Bone Marrow Sa A, Wang MD Jeffrey L. Jorgensen, MD, PhD Department of Hematopathology, UT M.D. Anderson Cancer Center, Houston,
More information2013 AAIM Pathology Workshop
2013 AAIM Pathology Workshop John Schmieg, M.D., Ph.D. None Disclosures 1 Pathology Workshop Objectives Define the general philosophy of reviewing pathology reports Review the various components of Bone
More informationCase Presentation No. 075
Case Presentation No. 075 Session 4. Myelodysplastic Syndrome Cristina Montalvo, MD Baylor College of Medicine Houston, Texas 2007 Workshop of Society for Hematopathology and European Association for Haematopathology
More informationDiagnosis of lymphoid neoplasms has been
Iranian Journal of Pathology (2007)2 (1), 1-61 Review Article Mehdi Nassiri Dep. of Pathology, University of Miami Miller School of Medicine, Miami, USA Abstract Correct diagnosis and classification of
More informationAbstract. Hematopathology / Improved Cytogenetics in Lymphoma. Key Words: Cytogenetics; B-cell lymphoma; CpG-oligonucleotide DSP30
Hematopathology / Improved Cytogenetics in Lymphoma Improved Detection Rate of Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia and Other Mature B-Cell Neoplasms With Use of CpG-Oligonucleotide
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationCollected: , PM Sent: , PM Received: , PM Preliminary: , PM. Notification Status: COMPREHENSIVE DIAGNOSIS
PATIENT Name:HIPAA, Compliant DOB: 03-25-1945 (60 yr) ID#: xxx-xx-0000 Sex: M Tel: xxx-xxx-xxxx SPECIMEN Your No:WS05-xxxx Case No:C05-00xxx Req. No:Txxxxx Collected: 06-08-05, PM Sent: 06-09-05, PM Received:
More informationCase Report De Novo CD5 Negative Blastic Mantle Cell Lymphoma Presented with Massive Bone Marrow Necrosis without Adenopathy or Organomegaly
Case Reports in Hematology Volume 2015, Article ID 146598, 6 pages http://dx.doi.org/10.1155/2015/146598 Case Report De Novo CD5 Negative Blastic Mantle Cell Lymphoma Presented with Massive Bone Marrow
More informationCYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING
INTRODUCTION The Cytogenetics Laboratory offers a comprehensive array of chromosome investigations for cancers, constitutional abnormalities, and prenatal and postnatal diagnosis. Analyses are performed
More informationBCR-ABL1 positive Myeloid Sarcoma Nicola Austin
BCR-ABL1 positive Myeloid Sarcoma Nicola Austin Cytocell UK & Ireland User Group Meeting Jesus College, Cambridge 4 th - 5 th April 2017 Myeloid Sarcoma WHO Classification Tumours of Haematopoietic and
More informationWBCs Disorders 1. Dr. Nabila Hamdi MD, PhD
WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features
More informationFlow cytometric evaluation of endoscopic biopsy specimens from patients with gastrointestinal tract B-cell lymphoma: a preliminary report
Jichi Medical University Journal Flow cytometric evaluation of endoscopic biopsy specimens from patients with gastrointestinal tract B-cell lymphoma: a preliminary report Satoko Oka,, Kazuo Muroi,, Kazuya
More informationHematopathology Specialty Conference Case #1
Hematopathology Specialty Conference Case #1 Robert (Bob) Ohgami, MD, PhD Assistant Professor Stanford University Disclosure of Relevant Financial Relationships Disclosure of Relevant Financial Relationships
More informationMyelodysplastic Syndrome Case 158
Myelodysplastic Syndrome Case 158 Dong Chen MD PhD Division of Hematopathology Mayo Clinic Clinical History 86 year old man Persistent borderline anemia and thrombocytopenia. His past medical history was
More informationImmunohistochemical Analysis Identifies Two Cyclin D1+ Subsets of Plasma Cell Myeloma, Each Associated With Favorable Survival
Hematopathology / CYCLIN D1 IMMUNOHISTOCHEMISTRY IN MYELOMA Immunohistochemical Analysis Identifies Two Cyclin D1+ Subsets of Plasma Cell Myeloma, Each Associated With Favorable Survival James R. Cook,
More informationCytogenetic Findings in Mantle Cell Lymphoma Cases With a High Level of Peripheral Blood Involvement Have a Distinct Pattern of Abnormalities
Hematopathology / MANTLE CELL LYMPHOMA Cytogenetic Findings in Mantle Cell Lymphoma Cases With a High Level of Peripheral Blood Involvement Have a Distinct Pattern of Abnormalities Mihaela Onciu, MD, 1*
More informationAggressive B cell Lymphomas
Aggressive B cell Lymphomas I have nothing to disclose. Disclosures Raju K. Pillai City of Hope National Medical Center Outline WHO 2016 Classification Large B cell Lymphomas New entities and changes in
More informationA Practical Guide To Diagnose B-Cell Lymphomas on FNAs. Nancy P. Caraway, M.D.
A Practical Guide To Diagnose B-Cell Lymphomas on FNAs Nancy P. Caraway, M.D. Major Factors Impacting Dx Lymphomas on Small Bxs Classification systems Immunophenotyping by multiprobe flow cytometry and
More informationBlastic NK-Cell Leukemia / Lymphoma
* * Blastic NK-Cell Leukemia / Lymphoma A Case Report Chun-Ming Lin Shu-Hui Wang Tseng-tong Kuo* Ching-Chi Chi Hsin-Chun Ho Hong-Shang Hong Blastic natural killer (NK) cell lymphoma / leukemia is a rare
More informationPrimary Cutaneous Follicle Center Lymphoma Associated With an Extracutaneous Dissemination
AJCP / Case Report Primary Cutaneous Follicle Center Lymphoma Associated With an Extracutaneous Dissemination A Cytogenetic Finding of Potential Prognostic Value Shivakumar Subramaniyam, PhD, Cynthia M.
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationLow-grade B-cell lymphoma
Low-grade B-cell lymphoma Patho-Basic 11. September 2018 Stephan Dirnhofer Pathology Outline Definition LPL, MBL/CLL/SLL, MCL FL Subtypes & variants Diagnosis including Grading Transformation Summary Be
More informationFluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)
PML/RARA t(15;17) Translocation Assay Result : nuc ish(pml 2)(RARA 2)[200] : 200/200(100%) interphase nuclei show normal 2O 2G signals for PML/RARA : is Negative for t(15;17)(q22;q21.1) 2 Orange 2 Green
More informationDoes the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
Histopathology 2012, 61, 1214 1218. DOI: 10.1111/j.1365-2559.2012.04351.x SHORT REPORT Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
More informationMolecular Advances in Hematopathology
Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important
More information